Prophylactic human papillomavirus vaccines

Journal of Clinical Investigation

Volumn 116, Issue 5, 2006, Pages 1167-1173

  Lowy, Douglas R ^a   Schiller, John T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; NEUTRALIZING ANTIBODY; SUBUNIT VACCINE; VIRUS PROTEIN; WART VIRUS VACCINE;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG INDUSTRY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; VIRUS PARTICLE; VIRUS RECOMBINATION;

ADOLESCENT; ADULT; AGE FACTORS; ANIMALS; CANCER VACCINES; CAPSID PROTEINS; DRUG INDUSTRY; FEMALE; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 33646421976     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI28607     Document Type: Review

References (53)

1. Pisani, P., Parkin, D.M., Munoz, N., and Ferlay, J. 1997. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomarkers Prev. 6:387-400.
2. Lowy, D.R., and Howley, P.H. 2001. Papillomaviruses. In Fields virology. D.M. Knipe and P.H. Howley, editors. Lippincott, Williams, & Wilkins. Philadelphia, Pennsylvania, USA. 2231-2264.
3. Zur Hausen, H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer. 2:342-350.
4. Bosch, F.X., Schiffman, M., and Solomon, D., editors. 2003. Future directions in epidemiologic and preventive research on human papillomaviruses and cancer. J. Natl. Cancer Inst. Monogr. 31:131.
5. Frisch, M. 2002. On the etiology of anal squamous carcinoma. Dan. Med. Bull. 49:194-209.
6. Gillison, M.L., and Shah, K.V. 2003. Chapter 9: role of mucosal human papillomavirus in nongenital cancers. J. Natl. Cancer Inst. Monogr. 31:57-65.
7. Schiffman, M., and Kjaer, S.K. 2003. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J. Natl. Cancer Inst. Monogr. 31:14-19.
8. Gillison, M.L., and Lowy, D.R. 2004. A causal role for human papillomavirus in head and neck cancer. Lancet. 363:1488-1489.
9. Szentirmay, Z., et al. 2005. Human papillomavirus in head and neck cancer: molecular biology and clinicopathological correlations. Cancer Metastasis Rev. 24:19-34.
10. Pfister, H. 2003. Chapter 8: human papillomavirus and skin cancer. J. Natl. Cancer Inst. Monogr. 31:52-56.
11. Yang, B.H., Bray, F.I., Parkin, D.M., Sellors, J.W., and Zhang, Z.F. 2004. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int. J. Cancer. 109:418-424.
12. Snijders, P.J., Steenbergen, R.D., Heideman, D.A., and Meijer, C.J. 2006. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J. Pathol. 208:152-164.
13. Wright, T.C., Jr., Cox, J.T., Massad, L.S., Twiggs, L.B., and Wilkinson, E.J. 2002. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JaMa. 287:2120-2129.
14. Bosch, F.X., Lorincz, A., Munoz, N., Meijer, C.J., and Shah, K.V. 2002. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55:244-265.
15. Munoz, N., et al. 2004. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer. 111:278-285.
16. Cates, W., Jr. 1999. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex. Transm. Dis. 26(4 Suppl.):S2-S7.
17. Baseman, J.G., and Koutsky, L.A. 2005. The epidemiology of human papillomavirus infections. J. Clin. Virol. 32(Suppl. 1):S16-S24.
18. Khan, M.J., et al. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97:1072-1079.
19. Littler, E., and Oberg, B. 2005. Achievements and challenges in antiviral drug discovery. antivir. Chem. Chemother. 16:155-168.
20. Roden, R.B., Ling, M., and Wu, T.C. 2004. Vaccination to prevent and treat cervical cancer. Hum. Pathol. 35:971-982.
21. Ehreth, J. 2005. The economics of vaccination from a global perspective: present and future. 2-3 December, 2004, Vaccines: all things considered, San Francisco, CA, USA. Expert Rev. Vaccines. 4:19-21.
22. Robbins, J.B., Schneerson, R., and Szu, S.C. 1995. Hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171:1387-1398.
23. Kirnbauer, R., Booy, F., Cheng, N., Lowy, D.R., and Schiller, J.T. 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. acad. Sci. U. S. A. 89:12180-12184.
24. Hagensee, M.E., Yaegashi, N., and Galloway, D.A. 1993. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. Virol. 67:315-322.
25. Rose, R.C., Bonnez, W., Reichman, R.C., and Garcea, R.L. 1993. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J. Virol. 67:1936-1944.
26. Kirnbauer, R., et al. 1993. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67:6929-6936.
27. Rose, R.C., Reichman, R.C., and Bonnez, W. 1994. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J. Gen. Virol. 75:2075-2079.
28. Roden, R.B.S., et al. 1996. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 70:5875-5883.
29. Breitburd, F., et al. 1995. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69:3959-3963.
30. Suzich, J.A., et al. 1995. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. acad. Sci. U. S. A. 92:11553-11557.
31. Kirnbauer, R., et al. 1996. Virus-like particles of Bovine Papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 219:37-44.
32. Koutsky, L.A., et al. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:1645-1651.
33. Villa, L.L., et al. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6:271-278.
34. Mao, C., et al. 2006. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 107:18-27.
35. Harper, D.M., et al. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 364:1757-1765.
36. De Villiers, E.M., Fauquet, C., Broker, T.R., Bernard, H.U., and zur Hausen, H. 2004. Classification of papillomaviruses. Virology. 324:17-27.
37. Roden, R.B.S., et al. 1996. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J. Virol. 70:3298-3301.
38. Greer, C.E., et al. 1995. Human papillomavirus (HPV) type distribution and serological response to HPV 6 virus-like particle in patients with genital warts. J. Clin. Microbiol. 33:2058-2063.
39. [No authors listed]. 2001. FDA vaccines and related biological products advisory committee. Center for Biologics Evaluation and Research meeting #88. November 28-29. Bethesda, Maryland, USA. http://www.fda.gov/ohrms/dockets/ac/ cber01. htm#Vaccines.
40. Stoler, M.H. 2003. Human papillomavirus biology and cervical neoplasia: implications for diagnostic criteria and testing. Arch. Pathol. Lab. Med. 127:935-939.
41. Harro, C.D., et al. 2001. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93:284-292.
42. Barr, E. 2005. Gardasil HPV vaccine. Presented at the Centers for Disease Control and Prevention, National Immunization Program meeting of the Advisory Committee on Immunization Practices. February 10-11. Atlanta, Georgia, USA.
43. Barr, E. 2006. Garadasil HPV vaccine. Presented at the Centers for Disease Control and Prevention, National Immunization Program meeting of the Advisory Committee on Immunization Practices. February 21-22. Atlanta, Georgia, USA.
44. Dubin, G. 2005. Enhanced immunogenicity of a candidate human papillomavirus (HPV) 16/18 L1 virus like particle (VLP) vaccine with novel AS04 adjuvant in preteens/adolescents. Presented at the 45th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC). December 16-19. Washington, DC, USA.
45. Dubin, G. 2006. Cervarix HPV vaccine. Presented at the Centers for Disease Control and Prevention, National Immunization Program meeting of the Advisory Committee on Immunization Practices. February 21-22. Atlanta, Georgia, USA.
46. Nardelli-Haefliger, D., et al. 2003. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J. Natl. Cancer Inst. 95:1128-1137.
47. Stanberry, L.R., et al. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661.
48. Garnett, G.P. 2005. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J. Infect. Dis. 191(Suppl. 1):S97-S106.
49. Freeman, H., and Wingrove, B. 2005. Excess cervical cancer mortality: a marker for low access to health care in poor communities. National Cancer Institute, Center to Reduce Cancer Health Disparities. Rockville, Maryland, USA. http://crchd.nci.nih. gov/initiatives/#Reducing. 79 pp.
50. Clifford, G.M., et al. 2005. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol. Biomarkers Prev. 14:1157-1164.
51. Ulmer, J.B., and Liu, M.A. 2002. Ethical issues for vaccines and immunization. Nat. Rev. Immunol. 2:291-296.
52. Goldie, S.J., et al. 2005. Cost-effectiveness of cervical-cancer screening in five developing countries. N. Engl. J. Med. 353:2158-2168.
53. Schiffman, M., and Castle, P.E. 2005. The promise of global cervical-cancer prevention. N. Engl. J. Med. 353:2101-2104.